An Uncontrolled Open Label Multicenter Phase II Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma (HCC).

Trial Profile

An Uncontrolled Open Label Multicenter Phase II Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma (HCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 12 Mar 2013 Planned End Date changed from 1 Apr 2013 to 1 Mar 2013, as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Sep 2012 Planned end date changed from 1 Nov 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top